

## **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings of claims in the application:

### **Listing of Claims:**

1. (Previously presented) A method for selectively inhibiting T-cell rolling in a human host, the method comprising administering a compound, at least a portion of which is immunogenic, that interferes with at least one of the following interactions: a CLA and E-selectin interaction, a LFA-1/ICAM interaction or a VLA/VCAM interaction.

2. (Original) The method of claim 1 wherein said compound is an immunostimulant.

3-20. Canceled

21. (Currently amended) The method according to claim 1, wherein the immunogenic compound includes an immunotherapeutic agent comprising an insoluble particulate antigen derived from isolated killed cells of amastigotes from at least one species of the *Leishmania* genus, the antigen comprising polypeptides having apparent molecular weights after total reduction and alkylation of about 73 kDa, about 80kDa and about 82 kDa.

22. (Previously presented) The method according to claim 21, wherein the isolated killed cells of amastigotes are derived from *Leishmania amazonensis*.

23. (Previously presented) The method according to claim 27, wherein the isolated killed cells of amastigotes are derived from *Leishmania venezuelensis*.

24. (Previously presented) The method according to claim 27, wherein the isolated killed cells of amastigotes are derived from *Leishmania brasiliensis*.

25. (Previously presented) The method according to claim 27, wherein the isolated killed cells of amastigotes are derived from *Leishmania chagasi*.

26. (Previously presented) The method according to claim 27, wherein the isolated killed cells of amastigotes are derived from *Leishmania amazonensis*, *Leishmania venezuelensis*, *Leishmania brasiliensis* and *Leishmania chagasi*.

27. (Withdrawn) The method according to claim 21, wherein the 73 kDa polypeptide comprises the amino acid sequence set forth as:

- (a) SEQ ID NO: 1, SEQ ID NO: 5, and SEQ ID NO: 6; or
- (b) SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14.

28. (Previously presented) The method according to claim 21, wherein the 73 kDa polypeptide of the antigen comprises the amino acid sequence set forth as SEQ ID NO: 1, SEQ ID NO: 5, and SEQ ID NO: 6.

29. (Withdrawn) The method according to claim 21, wherein the 73 kDa polypeptide of the antigen comprises the amino acid sequence set forth as SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14.

30. (Withdrawn) The method according to claim 21, wherein the 80 kDa polypeptide comprises the amino acid sequence set forth as:

- (a) SEQ ID NO: 1, SEQ ID NO: 3, and SEQ ID NO: 4; or
- (b) SEQ ID NO: 1, SEQ ID NO: 3, and SEQ ID NO: 10.

31. (Previously presented) The method according to claim 21, wherein the 80 kDa polypeptide of the antigen comprises the amino acid sequence set forth as SEQ ID NO: 1, SEQ ID NO: 3, and SEQ ID NO: 4.

32. (Withdrawn) The method according to claim 21, wherein the 80 kDa polypeptide of the antigen comprises the amino acid sequence set forth as SEQ ID NO: 1, SEQ ID NO: 3, and SEQ ID NO: 10.

33. (Withdrawn) The method according to claim 21, wherein the 82 kDa polypeptide comprises the amino acid sequence set forth as:

- (a) SEQ ID NO: 1 and SEQ ID NO: 2; or
- (b) SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.

34. (Previously presented) The method according to claim 21, wherein the 82 kDa polypeptide of the antigen comprises the amino acid sequence set forth as SEQ ID NO: 1 and SEQ ID NO: 2.

35. (Withdrawn) The method according to claim 21, wherein the 82 kDa polypeptide of the antigen comprises the amino acid sequence set forth as SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.

36. (Withdrawn) The method according to claim 21, wherein the immunotherapeutic agent comprises

(a) at least one 73 kDa polypeptide comprising the amino acid sequence set forth as:

(i) SEQ ID NOS: 1, SEQ ID NO: 5, and SEQ ID NO: 6;

or

(ii) SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14;

(b) at least one 80 kDa polypeptide comprising the amino acid sequence set forth as:

(i) SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4; or

(ii) SEQ ID NO: 1, SEQ ID NO: 3, and SEQ ID NO: 10;

and

(c) at least one 82 kDa polypeptide comprising the amino acid sequence set forth as:

(i) SEQ ID NO: 1 and SEQ ID NO: 2; or

(ii) SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.

37. (Previously presented) The method according to claim 21, wherein the immunotherapeutic agent comprises

(a) at least one 73 kDa polypeptide, comprising the amino acid sequence set forth as SEQ ID NOS: 1, SEQ ID NO: 5, and SEQ ID NO: 6,

(b) at least one 80 kDa polypeptide, comprising the amino acid sequence set forth as SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, and

(c) at least one 82 kDa polypeptide, comprising the amino acid sequence set forth as SEQ ID NO: 1 and SEQ ID NO: 2.

38. (Withdrawn) The method according to claim 21, wherein the immunotherapeutic agent comprises

(a) at least one 73 kDa polypeptide, comprising the amino acid sequence set forth as SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO:14;

(b) at least one 80 kDa polypeptide, comprising the amino acid sequence set forth as SEQ ID NO: 1, SEQ ID NO: 3, and SEQ ID NO: 10; and

(c) at least one 82 kDa polypeptide of the antigen comprising the amino acid sequence set forth as SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.

39. (New) A method for selectively inhibiting T-cell rolling in a human host, the method comprising administering an immunotherapeutic agent comprising an antigen derived from isolated cells of amastigotes from at least one species of the *Leishmania* genus, wherein the agent interferes with at least one of the following interactions: a CLA and E-selectin interaction, a LFA-1/ICAM interaction or a VLA/VCAM interaction.